Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimekizumab - UCB

Next Previous
Drug Profile

Bimekizumab - UCB

Alternative Names: Anti-IL-17-mAb-UCB; Anti-IL-17-monoclonal-antibody-UCB; Anti-interleukin-17-monoclonal-antibody-UCB; bimekizumab-bkzx; BIMZELX; Bimzelx; BKZ; CDP-4940; UCB-4940

Latest Information Update: 27 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Axial spondyloarthritis; Erythrodermic psoriasis; Plaque psoriasis; Pustular psoriasis
  • Registered Ankylosing spondylitis; Hidradenitis suppurativa; Non-radiographic axial spondyloarthritis; Psoriatic arthritis
  • No development reported Psoriasis
  • Discontinued Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 21 Oct 2025 UCB plans a BeSeen phase III trial for Palmoplantar pustulosis in November 2025 (NCT07219420)
  • 17 Sep 2025 Efficacy and adverse events data from a phase III BE HEARD EXT trial in Hidradenitis suppurativa released by UCB Biopharma
  • 21 May 2025 UCB initiates enrolment in the phase I BE CARING trial in Canada (SC) (NCT06888193)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top